Results 161 to 170 of about 5,561 (244)
Treatment of type II hyperlipoproteinemia with d-thyroxine
Atherosclerosis, 1976 The effectiveness of a new, almost l-thyroxine free preparation of d-thyroxine (Dynothel) was tested in 15 patients with Type IIa and 4 patients with Type IIb hyperlipoproteinemia. Eleven patients with Type IIa and 3 with Type IIb were responsive to treatment and showed an average 26% decrease in plasma TC. This decrement in plasma TC was mirrored in a
Alexander Rakow +4 more
openalex +4 more sources
Therapeutic failure in familial type II hyperlipoproteinemia
Metabolism, 1976 The extended use of diet and cholestyramine therapy in familial type II hyperlipoproteinemia was examined in patients who previously participated in a short-term, double-blind trial. A striking secondary failure in therapeutic response during 4 yr of use of this therapy was noted with plasma cholesterol rising an average of 15%.
Lee A. Witters +4 more
openalex +4 more sources
Cholestyramine in Type II Hyperlipoproteinemia
Annals of Internal Medicine, 1973 R. I. Levy
openalex +4 more sources
Kyrle's Disease and Type II Hyperlipoproteinemia [PDF]
Archives of Dermatology, 1980 Kyrle's disease is an uncommon dermatosis of hyperkeratotic papules, with a distinctive histologic picture characterized by the penetration of a keratotic plug into the dermis. We report a case of Kyrle's disease in association with type II hyperlipoproteinemia.
Kenneth J. Tomecki +2 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pseudohomozygous Type II Hyperlipoproteinemia
Dermatology, 1991Nodular xanthomas on both elbows and a streak-like xanthoma on the intergluteal area developed in a 4-year-old girl with type IIa hyperlipoproteinemia. She had no disease associated with secondary hypercholesterolemia and no family history of hypercholesterolemia. Her xanthomas regressed under fat restriction diet and cholestyramine therapy.
Y. Saito +4 more
openaire +3 more sources
Clofibrate in Type II Hyperlipoproteinemia
Acta Medica Scandinavica, 1976ABSTRACT. As part of a double‐blind randomized study, the safety and the lipid‐ and uric acid‐lowering effect of clofibrate have been evaluated in 28 patients with type II hyperlipoproteinemia (HLP). A highly significant reduction of serum cholesterol occurred in type II a and of serum triglyceride and cholesterol in type IIb HLP throughout the 60 ...
Hans Olaf Bang, Jørn Ditzel
openaire +3 more sources
Pseudohomozygous type II hyperlipoproteinemia
The Journal of Pediatrics, 1974Familial hypercholesterolemia (a form of familial type II hyperlipoproteinemia) is transmitted as a dominant trait with homozygotes presenting in childhood with marked elevation of LDL and planar xanthormas. We studied two patients who presented as children with marked elevation of LDL and planar xanthomas but who, after family studies and clinical ...
Robert I. Levy +3 more
openaire +3 more sources
Familial Hyperlipoproteinemia Type II
Nishi Nihon Hifuka, 1974両側肩甲部, 肘頭, 臀部, 下腿屈側, 膝蓋部, 第I, IV指間には扁平黄色腫, 両側手指基節部, 右アキレス腱部に結節性黄色腫を, 両手掌, 指腹部には腱に一致して縦に走る橙黄色の線条がみられ, その母, 兄, 姉にも扁平あるいは結節性黄色腫と高コレステロール血症がみられたfamilial hyperlipoproteinemia type IIと思われる21才, 女性例を報告した。なお血清脂質は, 総コレステロール484mg/dl, β-リポ蛋白1760mg/dl, 燐脂質450mg/dl, 遊離脂肪酸0.453mEq/l, トリグリセライト109mg/dlであつた。
Reiko MORISHITA, Masaaki TASHIRO
openaire +2 more sources
Sitosterol in Type II Hyperlipoproteinemia [PDF]
, 1976 In 1951, PETERSON reported that the increase of plasma cholesterol levels in chickens caused by cholesterol feeding can be prevented by including 1 % soybean sterols in the diet (18). Since then, numerous investigators have demonstrated a hypocholesterolemic action of plant sterols, especially beta-sitosterol, in experimental animals and man (2, 3, 7 ...
U. Gundert-Remy +9 more
openaire +1 more source